SomnoMed (ASX:SOM) said it will absorb the immediate costs from new US tariffs in the immediate term, according to a Monday filing with the Australian bourse.
The company, which manufactures its products in the Philippines, is assessing the evolving impact of the tariffs, the filing said.
SomnoMed reaffirmed its fiscal year revenue guidance of about AU$105 million, with earnings before interest, taxes, depreciation, and amortization expected in the range of AU$7 million to AU$9 million, the filing added.
Shares of the company fell 19% at market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。